Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Cisplatin
  • Creatinine
  • Urinary Bladder Neoplasms

abstract

  • Current formulas estimating CrCl tend to underestimate measured CrCl, especially in those older than 65 years. Depending on the formula used, up to 44% who actually received cisplatin-based chemotherapy based on measured CrCl would be deemed ineligible at present, potentially affecting survival outcomes. Methodology for determining CrCl and/or renal eligibility for cisplatin-based chemotherapy in patients with bladder cancer should be re-examined.

publication date

  • July 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.04.3091

PubMed ID

  • 16809735

Additional Document Info

start page

  • 3095

end page

  • 100

volume

  • 24

number

  • 19